Key Highlights: Implications: Biodeal’s ₹385 crore raise gives it the capital to scale up manufacturing, add new products, and enter more regulated markets, which should help it win bigger, longer-ter...
Key Highlights: Implications: If completed, the transaction would likely be a strong validation event for mid-sized Indian pharmaceutical businesses that combine branded generics, nu...
Key Highlights: Implications: Viatris is selling up to 92 million Biocon shares (about 5.6% of the company) in a secondary sale, so Biocon gets no money from it; the deal is priced at a di...
Key Highlights: Implications: Sun Pharma’s acquisition of Innovcare looks like a portfolio-building move in India: for about ₹271.2 crore, Sun is buying a growing busin...
